Avacta Therapeutics has announced new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase Ib trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase Ia part of the study. … Read More
Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC). AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More
Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More
